Table 1.
Baseline characteristics of all Caucasian polypoidal choroidal vasculopathy patients
| Total population (eyes) | Subtypes of PCV | P value | |||
|---|---|---|---|---|---|
| PCV in context nAMD (drusen; type A) | PCV and non-polypoidal type 1 CNV/BVN (type B) | Idiopathic PCV (type C) | |||
| Patients (eyes) | 66 (74) | 33 (37) | 17 (18) | 16 (19) | |
| Mean age at onset in years (range) | 73 (51–90) | 73 (51–90) | 70 (57–90) | 76 (58–89) | 0.165a |
| BCVA in ETDRS letters (±SD) | 66.3 (2.3) | 63.8 (3.5) | 62.1 (4.3) | 75.1 (4.1) | 0.082a |
| Male gender (%) | 25 (34) | 11 (30) | 9 (50) | 5 (26) | 0.239b |
| Subjective symptoms (%) | 0.292c | ||||
| Blurred vision | 36 (48.6) | 22 (59.5) | 8 (44.4) | 6 (31.6) | |
| Spot in the field of vision | 10 (13.5) | 2 (5.4) | 4 (22.2) | 4 (21.1) | |
| Metamorphopsia | 9 (12.2) | 4 (10.8) | 3 (16.7) | 2 (10.5) | |
| Other | 18 (24.3) | 8 (21.6) | 3 (16.7) | 7 (36.8) | |
| None | 1 (1.4) | 1 (2.7) | - | - | |
| Median follow-up duration in days (range) | 343 (14–1704) | 344 (14–816) | 281 (35–1704) | 349 (38–840) | 0.919 d |
aOne-way ANOVA
bX2 test
cFisher’s exact test
dKruskal-Wallis test
BCVA, best-corrected visual acuity; ETDRS, Early Treatment of Diabetic Retinopathy Study; n, number of eyes; PCV, polypoidal choroidal vasculopathy; SD, standard deviation